Adaptive Biotechnologies Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2017
Net Income	-59.5	-159.49	-225.25	-200.19	-207.28	Upgrade
Depreciation & Amortization	17.83	19.26	22.23	20.92	13.95	Upgrade
Asset Writedown & Restructuring Costs	-	7.21	25.43	-	-	Upgrade
Loss (Gain) From Sale of Investments	-2.51	-8.21	-9.18	0.74	7.23	Upgrade
Stock-Based Compensation	51.48	53.61	62.91	55.48	43.25	Upgrade
Other Operating Activities	4.48	9.87	13.73	10.65	6.93	Upgrade
Change in Accounts Receivable	-8.65	-3.74	2.03	-22.65	-7.36	Upgrade
Change in Inventory	-1	5.37	-2.84	0.82	-5.2	Upgrade
Change in Accounts Payable	0.67	0.67	-5.41	7.11	3.94	Upgrade
Change in Unearned Revenue	-36.75	-10.48	-29.29	-56.5	-57.73	Upgrade
Change in Other Net Operating Assets	-12.04	-9.28	-10.68	-0.33	9.53	Upgrade
Operating Cash Flow	-45.99	-95.21	-156.32	-183.95	-192.73	Upgrade
Capital Expenditures	-2.96	-3.66	-10.7	-16.35	-61.75	Upgrade
Investment in Securities	40.91	81.46	140.34	19.25	242.96	Upgrade
Investing Cash Flow	37.95	77.79	129.65	2.91	181.21	Upgrade
Issuance of Common Stock	30.4	0.24	2.25	7.89	26.72	Upgrade
Other Financing Activities	-	-	-	124.38	0.43	Upgrade
Financing Cash Flow	30.4	0.24	2.25	132.27	27.15	Upgrade
Net Cash Flow	22.37	-17.18	-24.43	-48.78	15.63	Upgrade
Free Cash Flow	-48.95	-98.88	-167.02	-200.29	-254.47	Upgrade
Free Cash Flow Margin	-17.67%	-55.25%	-98.09%	-108.09%	-164.87%	Upgrade
Free Cash Flow Per Share	-0.32	-0.67	-1.16	-1.41	-1.81	Upgrade
Cash Interest Paid	12.64	8.86	8.99	0.49	-	Upgrade
Levered Free Cash Flow	0.95	-24.48	-81.95	-90.17	-139.1	Upgrade
Unlevered Free Cash Flow	8.31	-17.24	-73.33	-87.53	-139.1	Upgrade
Change in Working Capital	-57.77	-17.45	-46.18	-71.55	-56.82	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.